Safety alertSource: FDA Drug Enforcement Reports
Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 1000-count bottles, Rx On
FDA has classified a Class II recall of Accord Healthcare's Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 1000-count bottles, NDC 16729-453-17, manufactured by Intas Pharmaceuticals. The recall reason listed is that the drug is subpotent.
Most relevant for: Patients prescribed this specific lot of levothyroxine 125 mcg for management of hypothyroidism.
Read the original at FDA Drug Enforcement ReportsSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More otolaryngology (ent) updates
- Updated AAO-HNS Guideline Revises Tinnitus Evaluation and ManagementOct 1, 2026
- Updated AAO-HNSF Guideline Sets Evidence-Based Tinnitus Management StepsOct 1, 2026
- Revision Rate for Inferior Turbinate Reduction Found to Be 4.3%Sep 30, 2026
- Systematic review finds sex differences in OSA diagnostic parametersSep 29, 2026
- Racial disparities found in facial paralysis diagnosis and treatmentSep 29, 2026